Aktuellt
SENASTE
Redeye comments on Scandion Oncology’s Q4 2023 report, with the company having recently presented its plan to drive SCO-101 towards a randomised controlled phase IIb trial in mCRC. We judge the company’s strategy as prudent, though it will need to address financing while running some CORIST part 3 extension cohorts in 2024e to prepare for phase IIb. We do some housekeeping in our model and leave our estimates and valuation largely unchanged.
LÄS MER
